Cargando…
Blocking extracellular Galectin-3 in patients with osteoarthritis
OBJECTIVE: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). METHODS: 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules)...
Autores principales: | Andrews, Alec R., Fernandes, Ana D., Brownmiller, Seth E., Hanna, Yousif, Fisher, Mark C., Huang, Christene A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909224/ https://www.ncbi.nlm.nih.gov/pubmed/31872160 http://dx.doi.org/10.1016/j.conctc.2019.100500 |
Ejemplares similares
-
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
por: DeFilipp, Zachariah, et al.
Publicado: (2019) -
431 Galectin-3 as a Biomarker and Potential Therapeutic Target in Biliary Atresia
por: Yoeli, Dor, et al.
Publicado: (2022) -
Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3
por: Weinmann, Daniela, et al.
Publicado: (2018) -
Regulation of Tumor Progression by Extracellular Galectin-3
por: Nangia-Makker, Pratima, et al.
Publicado: (2008) -
Extracellular Galectin-3 in Tumor Progression and Metastasis
por: Fortuna-Costa, Anneliese, et al.
Publicado: (2014)